These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 1396993

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. In vitro retinal and erythrocyte polyol pathway regulation by hormones and an aldose reductase inhibitor.
    Hotta N, Kakuta H, Koh N, Fukasawa H, Yasuma T, Awaya S, Sakamoto N.
    Diabetes Res Clin Pract; 1991 Oct; 14(1):29-35. PubMed ID: 1748061
    [Abstract] [Full Text] [Related]

  • 3. Pharmacological properties of fidarestat, a potent aldose reductase inhibitor, clarified by using sorbitol in human and rat erythrocytes.
    Sobajima H, Aoki T, Sassa H, Suzuki T, Taniko K, Makino M, Mizuno K, Suzuki T.
    Pharmacology; 2001 May; 62(4):193-9. PubMed ID: 11359994
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effect of epalrestat, an aldose reductase inhibitor, on the generation of oxygen-derived free radicals in neutrophils from streptozotocin-induced diabetic rats.
    Kashima K, Sato N, Sato K, Shimizu H, Mori M.
    Endocrinology; 1998 Aug; 139(8):3404-8. PubMed ID: 9681489
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effects of aldose reductase inhibitor (ONO-2235) on human erythrocyte sorbitol concentrations in 75 g oral glucose tolerance tests.
    Kamon N, Mabuchi H, Takeda R, Terashima H.
    Horm Metab Res; 1991 May; 23(5):226-9. PubMed ID: 1908433
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The role of sorbitol pathway and treatment effect of aldose reductase inhibitor ONO2235 in the up-regulation of cardiac M2-muscarinic receptors in streptozotocin-induced diabetic rats.
    Liu TP, Juang SW, Cheng JT, Tong YC.
    Neurosci Lett; 1991 May; 383(1-2):131-5. PubMed ID: 15936525
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
    Shindo H, Tawata M, Aida K, Onaya T.
    J Clin Endocrinol Metab; 1992 Feb; 74(2):393-8. PubMed ID: 1370506
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of an aldose reductase inhibitor, ONO-2235, insulin and their combination on the altered responsiveness to the nerve stimulation and agonists of the isolated atria of diabetic rats.
    Hashimoto H, Satoh N, Takiguchi Y, Nakashima M.
    J Pharmacol Exp Ther; 1990 May; 253(2):552-7. PubMed ID: 2159998
    [Abstract] [Full Text] [Related]

  • 19. Aldose reductase inhibitor ONO-2235 restores the alterations of bladder nerve growth factor and neurotrophin receptor p75 genetic expression in streptozotocin induced diabetic rats.
    Tong YC, Cheng JT.
    J Urol; 2007 Nov; 178(5):2203-7. PubMed ID: 17870109
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.